Vesikari T
University of Tampere Medical School, Finland.
Lancet. 1997 Nov 22;350(9090):1538-41. doi: 10.1016/S0140-6736(97)03254-6.
Rotaviruses are responsible for more diarrhoeal disease-associated mortality than any other single agent. Vaccination may therefore hold the key to combating diarrhoeal disease worldwide. Natural immunity to rotavirus infection indicates that rather than protection from reinfection such immunity gives rise to less severe and less frequent attacks of diarrhoea. Early attempts to design a rotavirus vaccine with bovine rotavirus failed because of poor efficacy in some developing countries. Research into rhesus rotavirus, particularly the high-titre rhesus rotavirus tetravalent (RRV-TV) vaccine, has given slightly better results. A stumbling block to truly effective oral vaccines seems to be immunogenicity in developing countries. If efficacy can be ensured by trials in the developing countries, money spent on rotavirus vaccines will be well spent.
轮状病毒导致的腹泻病相关死亡率高于任何其他单一病原体。因此,接种疫苗可能是全球对抗腹泻病的关键。对轮状病毒感染的自然免疫表明,这种免疫并非防止再次感染,而是会使腹泻发作不那么严重且频率降低。早期用牛轮状病毒设计轮状病毒疫苗的尝试在一些发展中国家效果不佳,因而失败。对恒河猴轮状病毒的研究,尤其是高滴度恒河猴轮状病毒四价疫苗(RRV-TV),取得了稍好的结果。真正有效的口服疫苗的一个障碍似乎是在发展中国家的免疫原性。如果能通过在发展中国家进行试验确保疗效,那么花在轮状病毒疫苗上的钱就花得值。